Dexcom G7 sensor integration offers more customers the ability to manage diabetes from their iPhone, for additional convenience

Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod^® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System.

With this latest integration, the Omnipod 5 Automated Insulin Delivery (AID) System combines the benefits of tubeless AID and Dexcom’s latest diabetes management technology, all conveniently controlled from an iPhone.

"This integration represents a major milestone in our commitment to providing innovative solutions for diabetes management,” said Eric Benjamin, Insulet Executive Vice President, Chief Product and Customer Experience Officer. “With the addition of the Dexcom G7 sensor to the Omnipod 5 App for iPhone, our U.S. customers have more choice with fewer devices to keep track of, making it easier than ever to manage their diabetes.”

Omnipod 5 proactively adjusts insulin delivery every five minutes, autocorrects for high glucose, and helps protect against lows*, day and night—even while you sleep. The Omnipod 5 App for iPhone, available in the U.S., offers full control of Omnipod 5 including the ability to bolus, change a Pod, adjust settings, access valuable insights, and more.

“The Omnipod 5 App for iPhone means less stress with better control! Plus, I feel like I lost a few pounds, since I don't have to carry around a Controller anymore,” joked Garrett Vogel, a nationally syndicated radio personality who has lived with type 1 diabetes for 30 years and has been using Omnipod 5 since 2023. Garrett was previously using Omnipod 5 with Dexcom G7 and the Controller. “I thought bolusing with the Controller was easy, but the Omnipod 5 App on my iPhone makes it even easier. I love it.”

The Omnipod 5 App with Dexcom G7 and Dexcom G6 compatibility is now available for download on the Apple App Store.

Insulet remains dedicated to advancing diabetes technology and improving the lives of people with diabetes. For more information, please visit https://www.omnipod.com/innovation.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: insulet.com and omnipod.com.

*Brown S. et al. Diabetes Care. 2021;44:1630-1640. Sherr JL, et al. Diabetes Care. 2022. 45(8):1907–1910. Pasquel FJ et al. JAMA Network Open. 2024;8(2): e2459348. Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people with type 2 diabetes aged 18-75 years. Time above range and below range results measured by CGM.

©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250610766006/en/